8:42:48 AM PST - Monday, January 27th, 2020

Roche aims to 'underwhelm' on SMA drug price to challenge rivals  

By Editor - Tue Jan 14, 4:50 am

ZURICH/SAN FRANCISCO (Reuters) – Swiss drugmaker Roche plans to price its oral spinal muscular atrophy drug (SMA) risdiplam aggressively to challenge two of the world’s most expensive medicines, Biogen’s Spinraza and Novartis’s gene therapy Zolgensma. Spinraza’s list price is $750,000 in the first year, and $375,000 thereafter, while Novartis’s gene therapy for the genetic muscle wasting disease lists at $2.1 million, making it the drug industry’s most expensive one-time treatment. While Roche has not released risdiplam’s price, drug chief Bill Anderson said the Basel-based company will price the drug much as it did its hemophilia A medicine Hemlibra in 2017, when it undercut traditional therapies made by rivals NovoNordisk and Takeda to help win patients.

See the original post here:

Roche aims to 'underwhelm' on SMA drug price to challenge rivals

Leave a Reply

You must sign in to post a comment.